Health Technology

Sebia Receives U.S. FDA Clearance for the CAPILLARYS 3 DBS devices

Retrieved on: 
Friday, April 5, 2024
Other Health, General Health, Oncology, Biometrics, Technology, Medical Devices, Health Technology, Security, Online Privacy, Biotechnology, FDA, Other Technology, Health, Laboratory, Blood, Paper, DBS, DSM-IV codes, Food

Sebia, a global specialty diagnostic company providing innovative solutions for screening and diagnostics in oncology, metabolic diseases, genetic disorders and autoimmune diseases, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for CAPILLARYS 3 DBS devices.

Key Points: 
  • Sebia, a global specialty diagnostic company providing innovative solutions for screening and diagnostics in oncology, metabolic diseases, genetic disorders and autoimmune diseases, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for CAPILLARYS 3 DBS devices.
  • This qualitative analysis is performed by capillary electrophoresis with the CAPILLARYS 3 DBS automated instrument.
  • This offer provides laboratories a gain in operational efficiency with high throughput and a full traceability from DBS card up to the result through a cyber-secured environment.
  • This will help laboratories to make timely and accurate decisions for newborns” said Arnaud Collin, Sebia Group Vice President Global Regulatory Affairs & Quality.

BPGbio Presents Key Advances in its Oncology Pipeline related to the NAi Interrogative Biology Platform

Retrieved on: 
Friday, April 5, 2024
Oncology, Health, Technology, Health Technology, Artificial Intelligence, Pharmaceutical, Biotechnology, UBE2M, Oak Ridge National Laboratory, Neurology, Prostate cancer, Serum, FLNA, Drug discovery, Patient, GBM, Hospital, Research, Cancer, University, Hope, Deep learning, AACR, Clinical trial, Drug development, University of Tennessee, Immune system, Stanford University, Multimedia, Netherlands Architecture Institute

BPGbio, Inc., a leading biology-first AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced the application of its NAi Interrogative Biology® Platform across several drug and diagnostic applications, following successful collaborations with Stanford University, University of Tennessee, Oak Ridge National Laboratory, and several leading hospitals across Mexico.

Key Points: 
  • BPGbio, Inc., a leading biology-first AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced the application of its NAi Interrogative Biology® Platform across several drug and diagnostic applications, following successful collaborations with Stanford University, University of Tennessee, Oak Ridge National Laboratory, and several leading hospitals across Mexico.
  • The company will present four posters showcasing these research collaborations and provide updates on other internal research activities at the American Association for Cancer Research (AACR) Annual Meeting being held April 5-10, 2024, in San Diego, Calif.
  • This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20240405006693/en/
    A graphical representation of BPGbio's NAi Interrogative Biology Platform (Graphic: Business Wire)
    New data further validating the mitochondrial-centric effect of BPM31510 on the immune system.

MarinHealth Medical Center Becomes First Hospital in Northern California to Successfully Implant AVEIR™ DR, the World’s First Dual Chamber Leadless Pacemaker System

Retrieved on: 
Friday, April 5, 2024
Cardiology, Biotechnology, Surgery, General Health, Health, Medical Devices, Hospitals, Health Technology, VR, Communication, Infection, Atrial fibrillation, Risk, Immunosuppression, Patient, Cardiac electrophysiology, MD, Life, Stroke, Leg, Engineering, Heart, Dialysis, San Francisco Bay Area, FDA, Food, Medical device

MarinHealth Medical Center today announced the successful implantation of an AVEIR™ DR pacemaker system, becoming the first hospital in Northern California to insert the world’s first dual chamber leadless pacemaker system.

Key Points: 
  • MarinHealth Medical Center today announced the successful implantation of an AVEIR™ DR pacemaker system, becoming the first hospital in Northern California to insert the world’s first dual chamber leadless pacemaker system.
  • “MarinHealth is proud to be at the forefront in the clinical care of heart rhythm disorders.
  • Now, we are excited to become the first center in Northern California to offer dual chamber leadless pacemaker technology, which provides yet another state-of-the-art solution for heart rhythm patients in our community,” said Anita Chandrasena, MD , Chief Medical Officer of MarinHealth.
  • Roughly one-tenth the size of a traditional pacemaker, the dual chamber AVEIR leadless pacing system is made up of two devices: a ventricular (VR) and an atrial (AR) leadless pacemaker.

Verato names Andy Dé as Chief Marketing Officer

Retrieved on: 
Thursday, April 4, 2024
Data Management, Technology, Professional Services, Managed Care, Other Health, Health, Health Technology, Health Insurance, Data Analytics, Software, Hospitals, Tableau, GTM, GM, Growth, Science, Blue, Business, Artificial intelligence, University, Triple accreditation, Tableau Software, Harvard Business School, SAP, CPG, GE HealthCare, MBA, Engineering, CMO, Marketing, Alteryx, Management

Verato , the identity experts for healthcare, today announced the appointment of Andy Dé to the role of Chief Marketing Officer (CMO).

Key Points: 
  • Verato , the identity experts for healthcare, today announced the appointment of Andy Dé to the role of Chief Marketing Officer (CMO).
  • Dé will oversee the company’s go-to-market (GTM) strategy, planning and execution in his role leading the global marketing organization reporting to Clay Ritchey, Chief Executive Officer (CEO).
  • “I am humbled and honored to join Verato and bring my passion for building, transforming and growing world-class, high-performing global marketing teams to drive the continued rapid growth of adoption of Verato’s industry leading hMDM solutions,” said Andy Dé, CMO at Verato.
  • “I am thrilled to welcome Andy to the Verato team,” said Clay Ritchey, CEO of Verato.

IDEXX Laboratories to Release 2024 First Quarter Financial Results

Retrieved on: 
Thursday, April 4, 2024
Consumer, Health, Pets, Veterinary, Health Technology, Telephone, Webcast, IDXX, Idexx Laboratories, Laboratory

IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2024 first quarter results for Wednesday, May 1, 2024, before the market opens.

Key Points: 
  • IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2024 first quarter results for Wednesday, May 1, 2024, before the market opens.
  • The Company will conduct an analyst conference call beginning at 8:30 a.m.
  • Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q1 2024 Earnings Snapshot through a link on the IDEXX website, www.idexx.com/investors .
  • To listen to the live conference call, please dial 1-800-776-0420 or 1-773-305-6837 and reference passcode 951825.

Allurion Expands Virtual Care Suite to the United States

Retrieved on: 
Thursday, April 4, 2024
Women, Other Health, Other Technology, Men, Telemedicine, Virtual Medicine, Family, Medical Devices, Hospitals, Consumer, Fitness & Nutrition, Technology, General Health, Biotechnology, Diabetes, Surgery, Health, Apps, Applications, Health Technology, Bariatric surgery, Conference, Obesity, VCS, Patient, Research, Artificial intelligence, Digital health, Digital, NPS, Satellite navigation device

Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the commercial availability of its comprehensive Virtual Care Suite (VCS) in the United States.

Key Points: 
  • Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the commercial availability of its comprehensive Virtual Care Suite (VCS) in the United States.
  • In 2023, Allurion added Coach Iris, a 24/7 AI-powered weight loss coach, to the VCS, enabling automated, conversational coaching and a more personalized behavior change program tailored to patient needs.
  • “After witnessing the profound impact our technology has had globally, we are thrilled to launch the VCS in the United States.
  • As part of the launch, Allurion will also be unveiling a new version of Allurion Insights, the web-based dashboard that providers use to navigate the VCS.

Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer

Retrieved on: 
Friday, April 5, 2024
Surgery, Genetics, Clinical Trials, Health Technology, Biotechnology, Other Health, Health, Pharmaceutical, Oncology, Congress, Cystectomy, CDX, Patient, Roche, DNA, DFS, EAU, Bladder cancer, MIBC, NTRA, Survival rate, MRD, FDA, Food, Pharmaceutical industry

The analysis evaluates outcomes in muscle-invasive bladder cancer (MIBC) patients who tested serially negative with Signatera™, Natera’s personalized and tumor-informed molecular residual disease (MRD) test.

Key Points: 
  • The analysis evaluates outcomes in muscle-invasive bladder cancer (MIBC) patients who tested serially negative with Signatera™, Natera’s personalized and tumor-informed molecular residual disease (MRD) test.
  • Sponsored by Genentech, a member of the Roche group, IMvigor011 is a global, double-blind, randomized, Phase III trial, in which high-risk MIBC patients are serially tested with Signatera for up to 12 months post cystectomy.
  • Patients who test Signatera MRD-positive at any point during the 12-month surveillance window are randomized to the anti-PDL1 atezolizumab (Tecentriq®) vs. placebo.
  • “We believe the results of this trial will further demonstrate how Signatera can help personalize treatment decisions and improve outcomes for bladder cancer patients.

NorthStar Medical Radioisotopes Announces Participation in Upcoming 2024 Jefferies Radiopharma Innovation Summit

Retrieved on: 
Thursday, April 4, 2024
Oncology, Health, Hospitals, Health Technology, Radiology, Pharmaceutical, Biotechnology, Jefferies, Actinium-225, Radiopharmaceutical, Therapy, Cancer, NorthStar, CDMO, PET, Growth, Medical imaging

NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production, and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced that Frank Scholz, Ph.D., President and Chief Executive Officer will present at the upcoming 2024 Jefferies Radiopharma Innovation Summit.

Key Points: 
  • NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production, and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced that Frank Scholz, Ph.D., President and Chief Executive Officer will present at the upcoming 2024 Jefferies Radiopharma Innovation Summit.
  • “2024 and the next several years are pivotal for NorthStar as we expand our capabilities in the rapidly growing radiopharmaceuticals industry,” said Frank Scholz, Ph.D., President and Chief Executive Officer of NorthStar Medical Radioisotopes.
  • Our radiopharmaceutical R&D lab is busy with both PET diagnostics and therapeutics work where sponsors are experiencing useful results as they work to improve upon their formulations and processes.
  • Please reach out to your Jefferies representative to schedule.

FPT Software Achieves Double Wins at Healthcare Asia Medtech Awards 2024

Retrieved on: 
Friday, April 5, 2024
Data Management, Health, Technology, Health Technology, Software, Networks, FPT Software, HITRUST, Pharmacy, HL7, AWS, HIPAA, ISO 13485, Multimedia, ISO, DICOM, FPT

Global IT firm FPT Software recently won two categories in the Healthcare Asia Medtech Awards 2024: the Digital Innovation of the Year - Vietnam and the Initiative Award - Vietnam.

Key Points: 
  • Global IT firm FPT Software recently won two categories in the Healthcare Asia Medtech Awards 2024: the Digital Innovation of the Year - Vietnam and the Initiative Award - Vietnam.
  • This marks the second consecutive year the firm has been honored with these awards, solidifying its position as a world-class service provider in the healthcare industry.
  • View the full release here: https://www.businesswire.com/news/home/20240404598004/en/
    Organized by Healthcare Asia, the premier industry magazine catering to hospital owners, investors, administrators, and policymakers across Asia, the annual Healthcare Asia Medtech Awards are designed to recognize and highlight outstanding medtech companies in the region that consistently surpass expectations by delivering groundbreaking innovations to their customers.
  • FPT Software is among over 250 applications this year from businesses across the Asia Pacific region and stands out as the sole nominee from Vietnam to claim two esteemed awards.

Jackson Healthcare Debuts on “100 Best Companies to Work For®” List by Fortune Media and Great Place To Work

Retrieved on: 
Thursday, April 4, 2024
Managed Care, Professional Services, Pharmaceutical, Consumer, Hospitals, Health Technology, Women, Nursing, Human Resources, Practice Management, Millennials, Health, Philosophy, Trust, Family, Organization, Culture, Workplace, Health care, Woman

Jackson Healthcare ®, a family of highly specialized healthcare staffing, search and technology companies, today announced that it has been named one of the 2024 Fortune 100 Best Companies to Work For®.

Key Points: 
  • Jackson Healthcare ®, a family of highly specialized healthcare staffing, search and technology companies, today announced that it has been named one of the 2024 Fortune 100 Best Companies to Work For®.
  • Based on associate feedback collected by Great Place To Work®, the global authority on workplace culture, the 100 Best Companies to Work For list recognizes organizations that have created strong workplace cultures and positive experiences for all.
  • Jackson Healthcare’s most recent survey found that 93 percent of associates consider it a great place to work, a figure well above Great Place To Work benchmarks.
  • “It’s a great honor for Jackson Healthcare to be named among this year’s 100 Best Companies to Work For.